The overexpression of BRD4 in cancer cells can induce abnormal expression of its downstream genes involving some pivotal oncogenes such as c-Myc and Bcl-2, which contributes to the occurrence and development of glioma, acute myeloid lymphoma (AML), breast cancer, and other tumors [[12], [13], [14], [15]]. This evidence concerns the gene BCL2 and central nervous system cancer.